ADMA Biologics, Inc. (ADMA) is a publicly traded Healthcare sector company. As of September 8, 2026, ADMA trades at $9.54 with a market cap of $2.15B and a P/E ratio of 15.38. ADMA moved -0.88% today. Year to date, ADMA is -47.70%; over the trailing twelve months it is -41.90%. Its 52-week range spans $7.21 to $25.67. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces ADMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
4 analysts cover ADMA: 0 strong buy, 3 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $17.00.
| Metric | Value |
|---|---|
| Price | $9.54 |
| Market Cap | $2.15B |
| P/E Ratio | 15.38 |
| EPS | $0.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.67 |
| 52-Week Low | $7.21 |
| Volume | 1.57M |
| Avg Volume | 0 |
| Revenue (TTM) | $510.17M |
| Net Income | $146.93M |
| Gross Margin | 57.38% |
4 analysts cover ADMA: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.